Curated News
By: NewsRamp Editorial Staff
June 22, 2026

NanoViricides Ships NV-387 Gummies for MPox Trial in DRC

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • NanoViricides' NV-387 oral gummies shipped for MPox trial, potentially positioning it as a broad-spectrum antiviral against multiple viruses.
  • NV-387, a broad-spectrum antiviral, shipped to DRC for Phase II MPox trial; patient enrollment starts after staff training.
  • This trial could lead to a new treatment for severe MPox and Ebola, improving health outcomes in affected regions.
  • NV-387 is a nanoviricide candidate that also shows potential against Ebola, expanding its antiviral reach beyond MPox.

Impact - Why it Matters

This news matters because MPox, particularly the severe Clade I strain in the Democratic Republic of Congo, poses a significant public health threat with limited treatment options. If successful, NV-387 could provide a much-needed broad-spectrum antiviral therapy not only for MPox but also for other viral diseases like Ebola. The development of a convenient oral gummy formulation may improve patient compliance and accessibility in resource-limited settings. For investors, the initiation of a Phase II trial marks a key milestone for NanoViricides, potentially de-risking its lead candidate and highlighting its platform's versatility in addressing multiple viral threats.

Summary

NanoViricides, Inc. (NYSE American: NNVC) has shipped its NV-387 Oral Gummies to the Democratic Republic of Congo for an upcoming Phase II clinical trial targeting MPox. The company, a clinical-stage nanomedicine firm, is working with its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners to prepare trial sites. Patient enrollment and dosing are expected to commence after staff training concludes in the coming weeks. The trial will evaluate the safety and efficacy of NV-387 against MPox caused by the human monkeypox virus, with a focus on the severe Clade I strain endemic to the DRC. Additionally, NV-387 is a broad-spectrum antiviral candidate proposed for Ebola virus infections, and its local availability could support outbreak response efforts. Successful development may position NV-387 as a potential treatment for multiple viral diseases, including MPox and Ebola.

NanoViricides specializes in creating nanomaterials for antiviral therapy, leveraging its nanoviricide technology licensed from TheraCour Pharma. Its lead drug candidate, NV-387, is being developed for respiratory infections like RSV, COVID-19, influenza, and other viral threats. The company also has advanced candidates for shingles (NV-HHV-1) and COVID-19 (NV-CoV-2 and NV-CoV-2-R). With a pipeline targeting numerous viruses—including HIV, hepatitis, rabies, herpes, and dengue—NanoViricides aims to address significant unmet medical needs. The DRC trial marks a critical step in advancing NV-387 into Phase II human trials, underscoring the company's commitment to combating emerging infectious diseases.

To view the full press release, visit https://ibn.fm/CTIZc. For more updates on NNVC, check the company’s newsroom at https://ibn.fm/NNVC.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Ships NV-387 Gummies for MPox Trial in DRC

blockchain registration record for this content.